Evidence map›Paper›PMID 40699274›Full record

ReviewPharmacological reports : PR2025

Protective effect and molecular mechanisms of magnolol in ischemic stroke.

Xu Wang, Yukun Xiao, Qiyi Ta, Zhen Wei, Chunshu Rong, Haoxu Ren, Ziqiao He, Dexi Zhao, Jinhua Li

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xu Wang *Department of Encephalopathy, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, China.ORCID http://orcid.org/0009-0007-7157-7156
Yukun Xiao *Hangzhou Youyitang Traditional Chinese Medicine Outpatient Department Co., Ltd, Hangzhou, Zhejiang, 310000, China.
Qiyi Ta *College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, 130117, China.
Zhen WeiMedical Intensive Care Unit, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, China.
Chunshu RongDepartment of Encephalopathy, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, China.
Haoxu RenDepartment of Encephalopathy, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, China.
Ziqiao HeSchool of Public Health, Jilin University, Changchun, Jilin, 130021, China.
Dexi ZhaoDepartment of Encephalopathy, Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130021, China. zdx02@163.com.
Jinhua LiSchool of Public Health, Jilin University, Changchun, Jilin, 130021, China. jinhua1@jlu.edu.cn.ORCID https://orcid.org/0000-0003-0085-9168

Funding

Science and Technology Development Bureau of Jilin Province, China 20220505042ZP
6 · The paper itself

Abstract

The treatment methods for ischemic stroke (IS) are currently limited, posing a significant challenge to global healthcare. Tissue-type plasminogen activator remains the only effective drug for IS, yet its use is restricted by narrow therapeutic windows and potential complications, limiting its benefits to a small fraction of patients. Magnolol, the primary bioactive compound extracted from the bark of Magnolia officinalis, a traditional Chinese medicinal herb, has demonstrated promising neuroprotective properties in IS models. This review synthesizes recent findings regarding the neuroprotective effects of magnolol in IS models. It highlights its advantages across various protective mechanisms, including antioxidant activity, anti-inflammatory effects, inhibition of autophagy, prevention of cell death, protection of the blood-brain barrier, and promotion of neuronal survival. By elucidating these mechanisms, this review highlights the therapeutic potential of magnolol in IS and provides a theoretical foundation for future experimental and clinical studies.

Indexed as

Biphenyl CompoundsBrain IschemiaIschemic StrokeLignansNeuroprotective AgentsStrokeAnimalsAntioxidantsAutophagyBlood-Brain BarrierHumansAntioxidantsBiphenyl CompoundsLignansmagnololNeuroprotective AgentsCell deathCerebral ischemiaInflammationMagnololNeuroprotective effect

Identifiers

PMID40699274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.